Research

Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial

Charlotte Andersson¹ , Peter Weeke¹ , Bente Brendorp² , Lars Køber³ , Emil L Fosbøl¹ , Arya M Sharma⁴ , Nick Finer⁵ , Ian D Caterson⁶ , Richard A Rode⁷ , Philip T James⁸ and Christian Torp-Pedersen¹

¹Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark

²Department of Cardiology, Glostrup University Hospital, Denmark

³The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark

⁴University of Alberta, Royal Alexandra Hospital, Edmonton, Alberta, Canada

⁵Addenbrooke's Hospital, Institute for Metabolic Science, Cambridge, UK

⁶Institute of Obesity Nutrition & Exercise, University of Sydney, NSW Australia

⁷Abbott Laboratories, Abbott Park, Illinois, USA

⁸London School of Hygiene and Tropical Medicine, London, UK

author email corresponding author email

Nutrition & Metabolism 2009, 6:42doi:10.1186/1743-7075-6-42

Published:	14 October 2009

Abstract

Background and aims

Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied.

Methods and results

Data from a four week single-blind lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) study were analyzed. 2584 patients (24%) had diabetes mellitus (DM) only, 1748 (16%) had cardiovascular disease (CVD) only and 6397 (60%) had both DM + CVD. Uric acid concentrations (mean ± standard deviation) at screening were significantly higher among patients with CVD compared to patients without CVD (p < 0.0001): 369 ± 86 μmol/L, 374 ± 98 μmol/L and 342 ± 87 μmol/L in CVD only, CVD+DM and DM only groups, respectively. During treatment uric acid decreased significantly more in patients without DM (p < 0.0001): -15.0 μmol/L (95% confidence interval -17.7;-12.4), -4.6 μmol/L (-6.2;-3.0), and -6.6 μmol/L (-8.7;-4.5) in CVD only, CVD+DM, and DM only groups, respectively. In patients who failed to lose weight, sibutramine induced lower uric acid levels, but greater weight loss and diabetes were associated with smaller falls in blood uric acid levels; decreasing fasting and urinary glucose concentrations in diabetes were associated with increases in uric acid levels.

Conclusion

A four week daily intake of sibutramine and life style changes was associated with significant reductions in mean uric acid levels. Changes in renal glucose load in diabetes seem to counteract a potential uricosuric effect of sibutramine.

Trial Registration

The trial is registered at ClinicalTrial.gov number: NCT00234832.